Respiratory Treatment and Prevention (Advances in Experimental Medicine and Biology)

Advs Exp. Medicine, Biology - Neuroscience and Respiration (2016) 27: 87–88
DOI 10.1007/5584_2016
#Springer International Publishing Switzerland 2017

Index

A
Adolescents, 81–84
Air pollution, 10, 11, 14–16
Airway collapse, 65
Airway obstruction, 64
Antituberculotics, 22
Aspergillosis, 27–32
Aspergillus fumigatus, 29, 30, 32, 59
Asthma, 83

B
Bacteria, 20, 24, 48–51, 54, 59
Bronchoalveolar lavage fluid (BALF), 2–6, 28, 30, 74

C
Cardiopulmonary disease, 9–16
Cefotaxime, 48–50
Cerebrospinal fluid (CSF), 53–60
Chronic bronchitis, 42, 82–84
Cigarette smoking (CS), 73–79, 81–84
City, 11, 12, 14, 82, 83
CSF.SeeCerebrospinal fluid (CSF)

D
Diagnosis/diagnostics, 3, 5, 19–24, 27–32, 36–39, 44, 45,
54, 55, 58, 60, 64, 66, 75, 79, 82
DNA, 31, 48–50, 53–60

E
ELISA.SeeEnzyme-linked immunosorbent assay
(ELISA)
Encephalitis, 54, 58, 59
Enzyme-linked immunosorbent assay (ELISA), 3, 28, 29,
38, 39, 75

G
Galactomannan (GM) antigen, 28–32
Gentamicin, 48–51
Granulocytes, 48, 50, 51

H
Health care,

I

Infection, 10, 20–24, 28–32, 36–39, 42–44, 47, 48, 50, 54,

58–60, 75

Inflammation, 51, 74, 79

L

Life style, 64, 84

Lungs, 2, 3, 5, 6, 21–24, 28, 50, 75, 79, 84

cancer, 9–16, 74

M

Malaria

parasites, 36–39

symptoms, 36–39, 41

treatment, 36, 37, 43, 44

Malondialdehyde (MDA), 74–79

Mandibular advancement appliance (MAA),

63–69

Metagenomics analysis, 53–60

Mosquito, 36

Mycobacteriosis, 23

N

Neutrophil extracellular traps (NETs), 47–51

Next-generation sequencing (NGS), 53–60

Non-tuberculous mycobacteria (NTM), 19–24

O

Osteoprotegerin (OPG), 1–6

P

Particulate matter (PM), 10–16

Pathogens, 20, 22, 24, 48, 49, 54, 55,

58, 59

Phagocytosis, 51

Pollutant concentration, 11, 12, 15

Population attributable fraction, 11, 12

Premature death, 10

Prophylaxis, 40, 43, 44

R

Respiratory tract, 2, 5, 24, 28–31, 74, 83

87